Arian Lundberg
Has grant
Assistant Professor at KTH Royal Institute of Technology
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Prostate Cancer Foundation Young Investigator Award
Open Date: 2024-11-01
Close Date: 2027-11-01
Grant: Close
Prostate Cancer Program Research Pilot Grant
Open Date: 2022-06-01
Close Date: 2023-06-01
Positions (2)
Arian Lundberg
KTH Royal Institute of Technology
2 months ago
KTH Royal Institute of Technology is recruiting a doctoral student for a project in multiomics, machine learning, and cancer bioinformatics at KTH/SciLifeLab in Stockholm. The project sits within the third-cycle subject Bio Biotechnology – Cancer Bioinformatics and focuses on precision medicine, cancer progression, and the tumor microenvironment, with an emphasis on genitourinary cancers. The research will combine bioinformatics-driven analyses, multi-omics data integration, and machine learning methods to investigate factors contributing to tumor progression and their links to cancer progression. The work is especially relevant for candidates interested in cancer biology, computational biology, translational research, and data-intensive biomedical discovery. Collaboration with clinical and translational researchers may be part of the project. Supervision is proposed by Assist Prof. Arian Lundberg and Prof. Cecilia Williams . The successful candidate will join an active research environment at KTH/SciLifeLab in Stockholm and will work in a setting that values independent research, teamwork, and scientific communication. Eligibility requires a second-cycle degree or equivalent qualification according to Swedish doctoral admission rules. A master’s degree in bioinformatics, computational biology, or a related field is required, together with a strong background in cancer biology. Practical skills in Bash, R, and/or Python are essential for analysis and multiomics integration. Candidates must also have strong English communication skills and an English level equivalent to English B/6 . Two academic or research references are required, including one from a previous supervisor. Selection will prioritize candidates who can work independently, collaborate effectively, analyze complex issues, show initiative, and manage multiple tasks. Experience with machine learning, multiomics integration, interdisciplinary research, clinical or patient data, HPC, and bioinformatics pipelines is advantageous. The position is a temporary full-time doctoral appointment with salary according to KTH’s doctoral student salary agreement. Applications must be submitted through KTH’s recruitment system by 2026-09-12 . Required documents include diplomas and transcripts, evidence of language qualifications, a CV, an application letter describing research interests and future goals, and representative publications or technical reports.
2 months ago
Arian Lundberg
KTH Royal Institute of Technology
9 months ago
A joint postdoctoral position is available at KTH Royal Institute of Technology and SciLifeLab in Stockholm, Sweden, in collaboration with Golnaz Taheri’s lab. This opportunity is funded by Digital Futures and focuses on the intersection of artificial intelligence, digital health, and cancer research. The research groups involved bring together expertise in AI and machine learning development, medical bioinformatics, biomarker discovery, cancer precision medicine, and clinical translation. The shared goal is to develop innovative tools that can make a real difference for patients, particularly in the field of precision medicine and diagnostics. The position is ideal for candidates with a strong background in computer science, bioinformatics, medical science, or related disciplines, and who are interested in applying AI and machine learning to solve challenges in cancer research and digital health. The collaborative environment at KTH and SciLifeLab offers access to cutting-edge resources and a vibrant research community. The position is fully funded by Digital Futures, though specific details about the stipend or salary are not provided in the announcement. Applicants should have a PhD in a relevant field and demonstrate experience in AI, machine learning, digital health, cancer research, or precision medicine. Strong research skills and the ability to work collaboratively across disciplines are highly valued. The application deadline is February 9th, 2026. Interested candidates are encouraged to review the official LinkedIn announcement for further details and to prepare their application materials accordingly.
9 months ago
Articles (18)
Year:
2026
Year:
2026
Hierarchical clustering analyses of benign, localized, and mCRPC tumors representing the expression of neuroendocrine marker genes (NE), androgen-related genes (AR), and genes related to squamous (SQUAM) differentiation
Year:
2025
Purpose: Although numerous biology-driven subtypes have been described previously in metastatic castration-resistant prostate cancer (mCRPC), unsupervised molecular subtyping based on gene expression has been less studied, especially using large cohorts. Thus, we sought to identify the intrinsic molecular subtypes of mCRPC and assess molecular and clinical correlates in the largest combined cohort of mCRPC samples with gene expression data available to date. Experimental Design: We combined and batch-effect corrected gene expression data from four mCRPC cohorts from the Fred Hutchinson Cancer Research Center ( N = 157), a small-cell neuroendocrine (NE) prostate cancer (SCNC)–enriched cohort from Weill Cornell Medicine ( N = 49), and cohorts from the Stand Up 2 Cancer/Prostate Cancer Foundation East Coast Dream Team ( N = 266) and the West Coast Dream Team ( N = 162). Results: Hierarchical clustering of RNA-sequencing data from these 634 mCRPC samples identified two distinct adenocarcinoma subtypes, one of which (adeno-immune) was characterized by higher gene expression of immune pathways, higher CIBERSORTx immune scores, diminished ASI benefit, and non–lymph node metastasis tropism compared with an adeno-classic subtype. We also identified two distinct subtypes with enrichment for an NE phenotype, including an NE-liver subgroup characterized by liver metastasis tropism, PTEN loss, and APC and SPOP mutations compared with an NE-classic subgroup. Conclusions: Our results emphasize the heterogeneity of mCRPC beyond currently accepted molecular phenotypes, and suggest that future studies should consider incorporating transcriptome-wide profiling to better understand how these differences impact treatment responses and outcomes.
Year:
2025
Supplemental Table 1: Median, Inter-Quartile Range (IQR), and 25th and 75th percentiles for Figure 2. Supplemental Table 2: Median, Inter-Quartile Range (IQR), and 25th and 75th percentiles for Figure 3. Supplemental Table 3: Proportions for Figure 4. Supplemental Table 4: Proportions for Figure 5.
Year:
2025
At high doses, alkylating drugs' toxicity leads to testicular atrophy and spermatogonial stem cells depletion, rendering survivors of childhood cancers infertile, as a recognized late effect. We used in-vivo experimental models to identify early gonadotoxic effects induced by cyclophosphamide (CPA) on prepubertal testes and to investigate if a treatment with antioxidants could reduce that toxicity. Effects were estimated by histological evaluation and whole-transcriptome RNA-sequencing (RNA-seq) of sacrificed animals at 8 hours intervals. Sixty pre-pubertal mice were randomly assigned to 1) intraperitoneal treatment with 100 mg/Kg CPA; 2) CPA in addition to antioxidants (AO) L-Carnitine (LC 50mg/kg) and N-acetyl cysteine (NAC 50); 3) AO alone; 4) control receiving saline solution (Ctrl) (N=15 for each group). Three additional animals were used for baseline assessments. On histology, changes were evident at 32 hours post-treatment. However, RNA-seq analyses revealed that the molecular impact of CPA occurred early within the first 16 hours of exposure to the drug, and that protective effects of AO in combined CPA therapy (CPA+AO) could be achieved during that period. This study demonstrates side effects of CPA on testicular tissue in the first 48 hours on transcriptional scale. Our findings indicate that early administration of AO can mitigate CPA-induced testicular damage in-vivo and suggest that protective treatments against prepubertal testis damage could be developed. However, such protective treatment should not interfere with the desired cytotoxic effects on the malignancies, thus further research is needed to evaluate the timing and how safe administration of the protectant could be achieved for medical treatment.
Year:
2025
Supplementary Figure 6 shows clinical data analysis of neoadjuvant androgen axis inhibition in primary prostate cancer as well as expression analysis of AR, MHCI, and IFNG activity in mHSPC clinical samples.
Year:
2025
Year:
2025
Supplementary Figure 6 shows clinical data analysis of neoadjuvant androgen axis inhibition in primary prostate cancer as well as expression analysis of AR, MHCI, and IFNG activity in mHSPC clinical samples.
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (34)
Kenny A. Rodriguez-Wallberg
Karolinska Institutet
Thomas O'Loughlin
Icahn School of Medicine at Mount Sinai
Meng Zhang
Assistant Professor of Urology
Emory University
Davide Ruggero
Professor
University of California
Alec Paschalis
Institute of Cancer Research
David A. Quigley
Assistant Professor
University of California, San Francisco
Joshua Lang
Professor
University of Wisconsin-Madison
Wilbert Zwart
Senior Groupleader / professor
Eindhoven University of Technology
Luke Gilbert
Assistant Professor
University of California, San Francisco
Alan Ashworth
University of California, San Francisco
Zheng Xia
Associate Professor
University of Texas at Austin
Alexander W. Wyatt
Assistant Professor
The University of British Columbia
Matthew Rettig
Professor
University of California, Los Angeles
Adam Sharp
Team Leader
Institute of Cancer Research
Shuang G. Zhao
University of Wisconsin-Madison
Li Zhang
Professor
UCSF
Kim Chi
Chief Medical Officer
BC Cancer
Adam Sowalsky
Senior Investigator
National Cancer Institute
Amir Hesam Eskafi Noghani
Karolinska Institutet
Michelle Badura
Lecturer
Santa Clara University
Duygu Kuzuoglu Ozturk
Assistant Prof
Sabancı University
Johann S de Bono
Head of Clinical Studies Division
Institute of Cancer Research
Raunak Shrestha
Assistant Professor
Uniformed Services University of the Health Sciences
Tomasz Michal Beer
Oregon Health & Science University
Eric J. Small
University of California, San Francisco
Lawrence Fong
Fred Hutch Cancer Center
Owen Witte
University Professor
University of California, Los Angeles
Matthew R. Cooperberg
University of California
Jonathan Chou
Assistant Professor
University of California, San Francisco
Felix Y. Feng
University of California
Christopher Evans
Professor
University of California, Davis
Mathieu Lupien
Senior Scientist
University Health Network
Rahul Aggarwal
University of California
Jessica Hawley
Assistant Professor
University of Washington
Make your next move.
Prepare your application
Review drafts before you send them.